BR112015020566A2 - moduladres de ror gama - Google Patents

moduladres de ror gama

Info

Publication number
BR112015020566A2
BR112015020566A2 BR112015020566A BR112015020566A BR112015020566A2 BR 112015020566 A2 BR112015020566 A2 BR 112015020566A2 BR 112015020566 A BR112015020566 A BR 112015020566A BR 112015020566 A BR112015020566 A BR 112015020566A BR 112015020566 A2 BR112015020566 A2 BR 112015020566A2
Authority
BR
Brazil
Prior art keywords
diabetes
gamma modulators
methods
ror gamma
modulators
Prior art date
Application number
BR112015020566A
Other languages
English (en)
Inventor
Wolfrum Christian
Carreira Erick
Cribiu Riccardo
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich filed Critical Eth Zuerich
Publication of BR112015020566A2 publication Critical patent/BR112015020566A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "moduladres de ror gama". a presente invenção refere-se a compostos de fórmula i, ou um sal farmaceuticamente aceitável do mesmo, caracterizado pelo fato de que pelo menos um de r8, r9, r10, r11 é -ora; para uso no tratamento ou na prevenção, supressão ou melhora de u-ma doença mediada pelo receptor ror gama em um indivíduo com necessidade do mesmo, em particular diabetes e distúrbios relacionados ao diabetes, especificamente diabetes tipo ii, métodos para sua produção, seu uso como suplemento dietético ou alimento funcional, assim como métodos de tratamento ou prevenção de tais doenças. 1/1
BR112015020566A 2013-03-18 2014-03-17 moduladres de ror gama BR112015020566A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13159736.1A EP2781217A1 (en) 2013-03-18 2013-03-18 ROR gamma modulators
PCT/EP2014/055284 WO2014147016A1 (en) 2013-03-18 2014-03-17 Ror gamma modulators

Publications (1)

Publication Number Publication Date
BR112015020566A2 true BR112015020566A2 (pt) 2017-07-18

Family

ID=48013744

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020566A BR112015020566A2 (pt) 2013-03-18 2014-03-17 moduladres de ror gama

Country Status (9)

Country Link
US (1) US20160287609A1 (pt)
EP (2) EP2781217A1 (pt)
JP (1) JP2016514715A (pt)
KR (1) KR20150130325A (pt)
CN (1) CN105338986A (pt)
AU (1) AU2014234467A1 (pt)
BR (1) BR112015020566A2 (pt)
RU (1) RU2015144338A (pt)
WO (1) WO2014147016A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014359324B2 (en) * 2013-12-05 2019-02-21 Lead Pharma Holding B.V. ROR gamma (RORy) modulators
AU2014365915C1 (en) * 2013-12-19 2019-04-04 Merck Patent Gmbh Tetrahydro-tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07126283A (ja) * 1993-09-03 1995-05-16 Kunio Tsuji 胆汁アルコール
PT832094E (pt) * 1995-06-07 2004-06-30 Genaera Corp Compostos de aminoesterol uteis como inibidores do permutador sodio/protao )nhe) metodos e composicoes farmaceuticas empregando estes inibidores e processos para avaliacao da eficacia inibidora de nhe dos compostos
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
JP2000026300A (ja) * 1998-07-02 2000-01-25 Pola Chem Ind Inc 血管内皮細胞保護医薬組成物
CA2368234A1 (en) * 1999-03-26 2000-10-05 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor
EP1218336A2 (en) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
EP1219294A4 (en) 1999-09-20 2005-01-26 ANTAGONISTS OF THE MELANIN CONCENTRATING HORMON
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
MXPA02008797A (es) 2000-03-14 2005-09-08 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina.
DE60110066T2 (de) 2000-06-16 2006-02-02 Smithkline Beecham P.L.C., Brentford Piperidine zur verwendung als orexinrezeptorantagonisten
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
JP4611019B2 (ja) * 2002-06-19 2011-01-12 カロ バイオ エービー 代謝異常治療のための新規な糖質コルチコイド受容体結合体
WO2006116814A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition and uses thereof
JP5292310B2 (ja) * 2007-01-19 2013-09-18 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５調節剤としての２３−置換胆汁酸およびその使用方法
CA2716922C (en) * 2008-02-26 2016-06-28 British Columbia Cancer Agency Branch Polyhydroxylated bile acids for treatment of biliary disorders
CN102712672B (zh) * 2009-08-25 2016-09-14 胆清医药有限公司 用于治疗胆疾病的多羟基化胆汁酸
NO2758060T3 (pt) * 2011-09-19 2018-04-28

Also Published As

Publication number Publication date
JP2016514715A (ja) 2016-05-23
KR20150130325A (ko) 2015-11-23
CN105338986A (zh) 2016-02-17
EP2976087A1 (en) 2016-01-27
WO2014147016A1 (en) 2014-09-25
RU2015144338A (ru) 2017-05-11
AU2014234467A1 (en) 2015-09-24
US20160287609A1 (en) 2016-10-06
EP2781217A1 (en) 2014-09-24

Similar Documents

Publication Publication Date Title
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112014003704A2 (pt) moduladores ror gama
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
IN2014DN06501A (pt)
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112015019919A2 (pt) compostos bicíclicos
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112014030325A8 (pt) uso de composição contendo derivado de verbenona para a obtenção de produto destinado ao tratamento ou prevenção de doença cerebral degenerativa, alimento funcional para prevenir ou tratar doença neurodegenerativa e composto
BR112018015851A2 (pt) composto, e, medicamento.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BRPI1011851A2 (pt) Composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, epara tratar uma doença
BR112017001803A2 (pt) aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos
BR112016027383A8 (pt) derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements